Amal Medicine - Academia.edu (original) (raw)

Papers by Amal Medicine

International Journal of Research in Medical Sciences, 2015

Metabolic syndrome is a cluster of risk factors for cardiovascular disease (CVD), including insul... more Metabolic syndrome is a cluster of risk factors for cardiovascular disease (CVD), including insulin resistance, obesity, hypertension, elevated triglycerides, and low levels of high density lipoprotein (HDL). 1 Metabolic syndrome is a strong predictor of type 2 diabetes, with an increased incidence rate of 5 to 7-fold. The risk of developing CVD is approximately doubled in the metabolic syndrome. 2 Obesity, in particular visceral adiposity, is known to be associated with insulin resistance and a heterogeneous disorder, MS. MS is a cluster of interrelated common clinical disorders, including hypertension, insulin resistance, glucose intolerance and dyslipidaemia, in addition to obesity. 3 It has been shown that visceral fat deposits are more metabolically active than their subcutaneous homologues, being particularly involved in the development of diseases associated with obesity, such as MS, type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD). 4 White adipose tissue plays a key role as an organ secreting numerous bioactive molecules called adipokines or adipocytokines. 5 The number of identified ABSTRACT Background: The metabolic syndrome (MS) is a cluster of interrelated common clinical disorders, including hypertension, insulin resistance, glucose intolerance and dyslipidaemia, in addition to obesity. Central obesity accompanied by insulin resistance is a keyfactor in the development of metabolic syndrome (MS) and future macro vascular complications. Adiponectin is the most abundant peptide secreted by adipocytes, being a key component in the interrelationship between adiposity, insulin resistance and inflammation. Hypoadiponectimia has already been associated with the risk of the MS in several populations. Plasma adiponectin level was measured in the current study to clarify its role as a biomarker for metabolic syndrome (MS). Methods: This study was conducted on 40 MS patients (Group I) compared with 20 age and sex matched healthy volunteers (Group II). All patients and controls were subjected to full medical history, clinical examination and laboratory investigations in addition to plasma adiponectin level. Results: Plasma adiponectin levels were significantly lower in subjects with MS when compared with subjects with no diagnosis of MS. There was significant negative correlation between plasma adiponectin and age, waist circumference, body mass index, systolic blood pressure, diastolic blood pressure, fasting blood sugar, insulin resistance, serum insulin, and triglycerides. Also there was significant positive correlation between plasma adiponectin and HDL. Conclusion: We conclude that adiponectin levels could help as a biomarker for cases of MS.

International Journal of Research in Medical Sciences, 2015

Metabolic syndrome is a cluster of risk factors for cardiovascular disease (CVD), including insul... more Metabolic syndrome is a cluster of risk factors for cardiovascular disease (CVD), including insulin resistance, obesity, hypertension, elevated triglycerides, and low levels of high density lipoprotein (HDL). 1 Metabolic syndrome is a strong predictor of type 2 diabetes, with an increased incidence rate of 5 to 7-fold. The risk of developing CVD is approximately doubled in the metabolic syndrome. 2 Obesity, in particular visceral adiposity, is known to be associated with insulin resistance and a heterogeneous disorder, MS. MS is a cluster of interrelated common clinical disorders, including hypertension, insulin resistance, glucose intolerance and dyslipidaemia, in addition to obesity. 3 It has been shown that visceral fat deposits are more metabolically active than their subcutaneous homologues, being particularly involved in the development of diseases associated with obesity, such as MS, type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD). 4 White adipose tissue plays a key role as an organ secreting numerous bioactive molecules called adipokines or adipocytokines. 5 The number of identified ABSTRACT Background: The metabolic syndrome (MS) is a cluster of interrelated common clinical disorders, including hypertension, insulin resistance, glucose intolerance and dyslipidaemia, in addition to obesity. Central obesity accompanied by insulin resistance is a keyfactor in the development of metabolic syndrome (MS) and future macro vascular complications. Adiponectin is the most abundant peptide secreted by adipocytes, being a key component in the interrelationship between adiposity, insulin resistance and inflammation. Hypoadiponectimia has already been associated with the risk of the MS in several populations. Plasma adiponectin level was measured in the current study to clarify its role as a biomarker for metabolic syndrome (MS). Methods: This study was conducted on 40 MS patients (Group I) compared with 20 age and sex matched healthy volunteers (Group II). All patients and controls were subjected to full medical history, clinical examination and laboratory investigations in addition to plasma adiponectin level. Results: Plasma adiponectin levels were significantly lower in subjects with MS when compared with subjects with no diagnosis of MS. There was significant negative correlation between plasma adiponectin and age, waist circumference, body mass index, systolic blood pressure, diastolic blood pressure, fasting blood sugar, insulin resistance, serum insulin, and triglycerides. Also there was significant positive correlation between plasma adiponectin and HDL. Conclusion: We conclude that adiponectin levels could help as a biomarker for cases of MS.